Date : 14th August, 2026

To,

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001.
BSE – Scrip Code: 517556

National Stock Exchange of India Limited
The Manager, Listing Department
"Exchange Plaza"
Bandra - Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE Symbol: PVP
Debt-18 PVL29A, 18PVL29

Dear Sir / Madam,

Sub: Notice of the 35th Annual General Meeting and Book Closure Dates of the Company.

Notice is hereby given that the 35th Annual General Meeting ("AGM") of the Members of the Company will be held on Monday, September 07, 2026, at 10:00 A.M. (IST) through Video Conferencing ('VC") /Other Audio-Visual Means ("OAVM"), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

In this regard the following shall be the relevant dates for the purpose of Cut-off/Record Date and the Book Closure dates:

Event	Date	Time
Relevant Date/Cut-off Date to vote on AGM resolution	31-08-2026	NA
Book Closure Period	01-09-2026 to 07-09-2026 (both days inclusive)	NA
Commencement of E-voting	04-09-2026	09:00 AM (IST)
End of E-voting	06-09-2026	05:00 PM (IST)
Annual General Meeting	07-09-2026	10:00 AM (IST)

Kindly acknowledge the receipt of the same and oblige.

Thanking you.
Yours Sincerely,
For **PVP VENTURES LIMITED**

PRASAD VEERA POTLURI
Digitally signed by PRASAD VEERA POTLURI
Date: 2026.08.14 16:51:59 +05'30'

Prasad V Potluri
Chairman and Managing Director
Encl: As above

PVP VENTURES LIMITED
CIN : L72300TN1991PLC020122

NOTICE TO SHAREHOLDERS

(Pursuant to Section 101 of the Companies Act, 2013)

Dear Members,

Notice is hereby given that the Thirty - Fifth Annual General Meeting ("AGM") of PVP Ventures Limited ("the Company") will be held on Monday, 07th September, 2026 at 10:00 AM (IST), through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact the following business.

The proceedings of the Thirty - Fifth Annual General Meeting shall be deemed to be conducted at the Registered Office of the Company at KRM Centre, 9th Floor, Door No. 2 Harrington Road, Chetpet, Chennai-600031, which shall be the deemed venue of the AGM.

ORDINARY BUSINESS:

1. ADOPTION OF AUDITED STANDALONE FINANCIAL STATEMENTS

To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditors thereon and to consider and if thought fit, to pass with or without modifications, the following resolution as an **Ordinary Resolution:**

RESOLVED THAT the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 and the Report of the Board of Directors and Auditors thereon, as circulated to the Members be considered and adopted.

2. ADOPTION OF AUDITED CONSOLIDATED FINANCIAL STATEMENTS

To receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Auditors thereon and to consider and if thought fit, to pass with or without modifications, the following resolution as an **Ordinary Resolution:**

RESOLVED THAT the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026 and the Report of the Auditors thereon, as circulated to the Members be considered and adopted.

3. APPOINTMENT OF M/S. CNGSN & ASSOCIATES LLP, CHARTERED ACCOUNTANTS, AS THE STATUTORY AUDITORS OF THE COMPANY FOR A TERM OF FIVE CONSECUTIVE YEARS

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution:**

RESOLVED THAT pursuant to the provisions of Sections 139, 141, 142 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable statutory provisions (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), and based on the recommendation of the Audit Committee and the Board of Directors, M/s. CNGSN & Associates LLP, Chartered Accountants (Firm Registration No. 004915S), who were appointed as the Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of the previous Statutory Auditors and who hold office till the conclusion of this Annual General Meeting, and being eligible for re-appointment and having furnished their written consent together with a certificate confirming that their appointment is in accordance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder, be and are hereby appointed as the Statutory Auditors of the Company to hold office for a term of five consecutive years, from the conclusion of this Annual General Meeting until the conclusion of the 40th Annual General Meeting of the Company to be held in the calendar year 2031, at such remuneration and reimbursement of out-of-pocket expenses as may be mutually agreed between the Board of Directors (including the Audit Committee thereof) and the Statutory Auditors.

RESOLVED FURTHER THAT the Board of Directors of the Company (including the Audit Committee thereof) be and is hereby authorised to finalise and revise the remuneration payable to the Statutory Auditors from time to time, in addition to reimbursement of applicable taxes and out-of-pocket expenses incurred in connection with the audit of the accounts of the Company.

RESOLVED FURTHER THAT any one of the Directors of the Company, or the Company Secretary of the Company, be and are hereby severally authorised to do all such acts, deeds, matters and things and to execute all such documents, forms and writings as may be considered necessary, proper or expedient to give effect to this resolution, including filing the necessary e-forms with the Registrar of Companies and making such intimations, filings and disclosures with the Stock Exchanges and other statutory authorities as may be required.

SPECIAL BUSINESS:

4. APPROVAL OF MATERIAL RELATED PARTY TRANSACTIONS

To consider and, if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution:**

RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Sections 177, 188 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014, and in accordance with the Company's Policy on Related Party Transactions, consent of the members of the Company be and is hereby accorded for entering into material related party transactions with the following entities, for an aggregate value not exceeding the amounts mentioned against their respective names, during the financial year 2026-2027 on such terms and conditions as may be mutually agreed, in the ordinary course of business and at arm's length basis:

SNo.	Name of the Company	Amount
1	M/s. BVR Malls Private Limited	200000000
2	M/s. PV Potluri Ventures Private Limited	200000000
3	M/s. Humain Healthtech Private Limited	10000000
4	M/s. Apta Medical Imaging Private Limited	10000000
5	M/s. Noble Diagnostics Private Limited	10000000
6	M/s. Biohygea Global Private Limited	100000000
7	M/s. Optimus Oncology Private Limited	100000000
8	M/s. 7 Med India Private Limited	100000000

RESOLVED FURTHER THAT the Board of Directors of the Company (including the Audit Committee) be and are hereby authorized to finalize the terms and conditions of the aforesaid transactions, and to do all such acts, deeds, matters and things as may be necessary or expedient to give effect to this resolution.

5. APPROVAL FOR CHANGE OF NAME OF THE COMPANY AND CONSEQUENTIAL ALTERATION OF THE MEMORANDUM OF ASSOCIATION AND ARTICLES OF ASSOCIATION

To consider and if thought fit, to pass the following as a **Special Resolution:**

RESOLVED THAT pursuant to the provisions of Sections 4, 13, 14 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act"), read with the Companies (Incorporation) Rules, 2014, the Companies (Management and Administration) Rules, 2014, applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and subject to the approval of the Central Government, Registrar of Companies, Stock Exchanges and such other statutory and regulatory authorities as may be necessary, consent of the Members of the Company be and is hereby accorded to change the name of the Company from **'PVP Ventures Limited' to 'Evervie Health Limited'** or such other name as may be approved by the Ministry of Corporate Affairs.

RESOLVED FURTHER THAT upon issuance of a fresh Certificate of Incorporation consequent upon change of name by the Registrar of Companies, Clause I of the Memorandum of Association of the Company be substituted with the following:

"I. The Name of the Company is **EVERVIE HEALTH LIMITED**."

RESOLVED FURTHER THAT wherever the name of the Company appears in the Memorandum of Association, Articles of Association and other constitutional documents, statutory registers, licences, approvals and records of the Company, the same shall stand substituted by the name Evervie Health Limited.

RESOLVED FURTHER THAT any one of the Directors of the Company or the Company Secretary be and is hereby severally authorised to make necessary filings with the Registrar of Companies, Stock Exchanges, SEBI and all other statutory authorities and to do all such acts, deeds, matters and things as may be necessary or expedient to give effect to this Resolution."

6. APPOINTMENT OF MS. SALONI KHANDELWAL (DIN: 00014590) AS A NON-EXECUTIVE INDEPENDENT DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass the following as an **Ordinary Resolution:**

RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, 161 and all other applicable provisions of the Companies Act, 2013 read with Schedule IV thereto, the Companies (Appointment and Qualification of Directors) Rules, 2014, Regulation 17 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and based on the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, Ms. Saloni Khandelwal (DIN: 00014590), who was appointed as an Additional Director (Non-Executive Independent Director) of the Company with effect from 15 May 2026 pursuant to Section 161 of the Companies Act, 2013 and who holds office up to the date of this Annual General Meeting and in respect of whom the Company has received a notice in writing under Section 160 of the Act proposing her candidature for the office of Director, be and is hereby appointed as a Non-Executive Independent Director of the Company, not liable to retire by rotation, to hold office for a first term of five (5) consecutive years commencing from 15 May 2026 up to 14 May 2031.

RESOLVED FURTHER THAT the Board of Directors (including any Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as may be necessary or expedient for giving effect to this Resolution."

7. APPOINTMENT OF MR. SRIVATSAN KALYANASUNDARAM (DIN: 11719208) AS A NON-EXECUTIVE INDEPENDENT DIRECTOR OF THE COMPANY

To consider and if thought fit, to pass the following as an **Ordinary Resolution:**

RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, 161 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule IV thereto, the Companies (Appointment and Qualification of Directors) Rules, 2014, Regulation 17 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), and based on the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, Mr. Srivatsan Kalyanasundaram (DIN: 11719208), who was appointed as an Additional Director in the capacity of Non-Executive Independent Director of the Company with effect from 15 May 2026 pursuant to Section 161 of the Act and who holds office up to the date of this Annual General Meeting and in respect of whom the Company has received a notice in writing under Section 160 of the Act proposing his candidature for the office of Director, be and is hereby appointed as a Non-Executive Independent Director of the Company, not liable to retire by rotation, to hold office for a first term of five (5) consecutive years commencing from 15 May 2026 up to 14 May 2031.

RESOLVED FURTHER THAT the Board of Directors (including any Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as may be necessary or expedient for giving effect to this Resolution.

8. APPOINTMENT OF DR. ELLEN FEEHAN (DIN: 11716152) AS AN EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER OF THE COMPANY AND APPROVAL OF REMUNERATION

To consider and, if thought fit, to pass the following as a **Special Resolution:**

RESOLVED THAT pursuant to the provisions of Sections 149, 152, 161, 196, 197, 198, 203 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Schedule V thereto, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Articles of Association of the Company and based on the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, Dr. Ellen Feehan (DIN: 11716152), who was appointed as an Additional Director of the Company with effect from 15th May, 2026 pursuant to Section 161 of the Act and who holds office up to the date of this Annual General Meeting, be and is hereby appointed as the Executive Director and Chief Executive Officer of the Company for a period of five (5) consecutive years commencing from 15th May, 2026 and ending on 14th May, 2031, not liable to retire by rotation, upon the terms and conditions including remuneration as may be approved by the Board of Directors from time to time.

RESOLVED FURTHER THAT in the event of absence or inadequacy of profits in any financial year during the tenure of office of Dr. Ellen Feehan, she shall be paid the remuneration, perquisites, allowances and other benefits as approved by the Board of Directors or the Nomination and Remuneration Committee as the minimum remuneration, in accordance with the provisions of Sections 196, 197 and other applicable provisions of the Companies Act, 2013 read with Schedule V thereto and subject to such statutory approvals as may be required.

RESOLVED FURTHER THAT the Board of Directors (which term shall include the Nomination and Remuneration Committee thereof) be and is hereby authorised to alter, vary, revise or enhance the remuneration, perquisites, allowances, incentives and other terms and conditions of appointment from time to time, provided the same are within the limits prescribed under the Companies Act, 2013 and other applicable laws.

RESOLVED FURTHER THAT any one of the Directors of the Company or the Company Secretary be and is hereby severally authorised to do all such acts, deeds, matters and things as may be necessary or expedient for giving effect to this Resolution.

9. APPOINTMENT OF DR. NEERAJA NAGARAJAN (DIN: 11716150) AS AN EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER OF THE COMPANY AND APPROVAL OF REMUNERATION

To consider and, if thought fit, to pass the following as an **Special Resolution:**

RESOLVED THAT pursuant to the provisions of Sections 152, 161 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with the Companies (Appointment and Qualification of Directors) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Articles of Association of the Company, and pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, Dr. Neeraja Nagarajan (DIN: 11716150), who was appointed as an Additional Director of the Company with effect from 1st July, 2026 pursuant to Section 161 of the Companies Act, 2013 and who holds office up to the date of this Annual General Meeting and in respect of whom the Company has received a notice in writing under Section 160 of the Act proposing her candidature for the office of Director, be and is hereby appointed as a Executive Director and Chief Operating Officer of the company for a period of Five years, not liable to retire by rotation, with effect from 1st July, 2026.

RESOLVED FURTHER THAT in the event of absence or inadequacy of profits in any financial year during the tenure of office of Dr. Neeraja Nagarajan, she shall be paid the remuneration, perquisites, allowances and other benefits as approved by the Board of Directors or the Nomination and Remuneration Committee as the minimum remuneration, in accordance with the provisions of Sections 196, 197 and other applicable provisions of the Companies Act, 2013 read with Schedule V thereto and subject to such statutory approvals as may be required.

RESOLVED FURTHER THAT the Board of Directors (which term shall include the Nomination and Remuneration Committee thereof) be and is hereby authorised to alter, vary, revise or enhance the remuneration, perquisites, allowances, incentives and other terms and conditions of appointment from time to time, provided the same are within the limits prescribed under the Companies Act, 2013 and other applicable laws.

RESOLVED FURTHER THAT any one of the Directors of the Company or the Company Secretary be and is hereby severally authorised to do all such acts, deeds, matters and things as may be necessary, desirable or expedient to give effect to this Resolution.

10. APPROVAL OF PAYMENT OF MANAGERIAL REMUNERATION TO MR. PRASAD V. POTLURI, CHAIRMAN AND MANAGING DIRECTOR AND PAYMENT OF FEES TOWARDS COLLATERAL SECURITIES AND PERSONAL GUARANTEES PROVIDED BY HIM

To consider and, if thought fit, to pass the following Resolution as a **Special Resolution:**

RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 and other applicable provisions, if any, of the Companies Act, 2013 ("Act") read with Schedule V thereto, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including Regulations 17(6)(e) and 23, and subject to such other approvals, permissions and sanctions as may be necessary, consent of the Members be and is hereby accorded for payment of managerial remuneration of Rs.5,00,00,000/- (Rupees Five Crores only) to Mr. Prasad V. Potluri (DIN: 00179175), Chairman and Managing Director, for the Financial Year 2026-27, notwithstanding that the Company has no profits or its profits are inadequate during the said financial year, in accordance with the provisions of Section 197 read with Section II of Part II of Schedule V to the Companies Act, 2013.

RESOLVED FURTHER THAT pursuant to the applicable provisions of the Companies Act, 2013, including Section 188, if applicable, and other applicable provisions, if any, of the Act read with the Rules made thereunder, the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including Regulation 23, the Company's Policy on Related Party Transactions and subject to such approvals, permissions and sanctions as may be necessary, consent of the Members be and is hereby accorded for payment of fees to Mr. Prasad V. Potluri at the rate of 2% per annum on the value of collateral securities provided by him and 1% per annum on the value of personal guarantees extended by him in connection with the loans, borrowings and other credit facilities availed by the Company, on such terms and conditions as may be approved by the Board of Directors from time to time.

RESOLVED FURTHER THAT the Board of Directors (which term shall include any Committee thereof) be and is hereby authorised to determine the manner of payment, alter, vary or modify the terms and conditions relating to the aforesaid remuneration and fees, provided that such variation shall be within the framework of the applicable provisions of the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws.

RESOLVED FURTHER THAT any one of the Directors of the Company or the Company Secretary be and are hereby severally authorised to do all such acts, deeds, matters and things, execute all documents, writings and agreements, file necessary forms and returns with the Registrar of Companies, Stock Exchanges and other statutory authorities and take all such actions as may be necessary, proper or expedient for giving effect to this Resolution.

11. TO APPROVE THE PVP VENTURES EMPLOYEE STOCK OPTION SCHEME 2026 ("PVP ESOP 2026")

To consider and if thought fit, to pass the following resolution as a **Special Resolution:**

RESOLVED THAT pursuant to the provisions of Section 62(1)(b) read with Rule 12 of the Companies (Share Capital and Debentures) Rules, 2014 and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and any other relevant rules thereunder, the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, as amended from time to time, read with all circulars and notifications issued thereunder, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the provisions of the Memorandum and Articles of Association of the Company, subject to other applicable statutory provisions, rules, regulations, guidelines and also subject to necessary approvals, consents, permissions and sanctions from the concerned Authorities and such terms and conditions as may be imposed by them, consent of the Members of the Company be and is hereby accorded to approve the PVP Ventures Limited Employee Stock Option Scheme 2026 ("PVP ESOP Scheme 2026") as presented before the Board and to create, offer, grant options in one or more tranches upto 2,00,00,000 Equity Shares of the company under the said Scheme at any time to or for the benefit of employees and Directors (excluding an employee/ director who is a promoter or belongs to the promoter group and independent director) of the Company exercisable on such terms and conditions as may be fixed or determined by the Nomination and Remuneration Committee in accordance with the PVP ESOP Scheme 2026 and guidelines or other applicable provisions of any law as may be prevailing at that time.

RESOLVED FURTHER THAT in case of any corporate action (s) such as rights issues, bonus issues, merger, sale of division and others, if any, the Company may be required to issue additional Equity Shares to the option grantees for the purpose of making a fair and reasonable adjustment to the options granted earlier, shall be deemed to be increased to the extent of such additional Equity Shares issued.

RESOLVED FURTHER THAT without prejudice to the generality of the above, the Nomination and Remuneration Committee is authorised to formulate, evolve, decide upon and implement the PVP ESOP Scheme 2026, determine the detailed terms and conditions of the aforementioned PVP ESOP Scheme 2026 including but not limited to the quantum of the Options to be granted and/or shares to be transferred per Employee, the number of Options and/or shares to be granted in each tranche, the terms or combination of terms subject to which the said Options and/or shares are to be granted/ issued, the exercise period, the vesting period, the vesting conditions, instances where such Options shall lapse, get cancelled or surrendered and to grant such number of Options, to such Employees of the Company, at such price, at such time and on such terms and conditions as set out in the PVP ESOP Scheme 2026;

RESOLVED FURTHER THAT the Nomination and Remuneration Committee or such other committees, for the purpose of giving effect to this resolution and related resolutions, be and are hereby authorized to sub-delegate to any executives/ officers of the Company to do all such acts, deeds, matters and things including authorizing or directing to appoint various intermediaries, advisors, consultants or representatives for effective implementation and administration of PVP ESOP Scheme 2026, as also to make applications to the appropriate authorities, parties and the institutions for their requisite approvals and all other documents required to be filed in the above connection and to settle all such questions or difficulties whatsoever which may arise and take all such steps and decisions, etc., as may be necessary in this regard.

RESOLVED FURTHER THAT the Nomination and Remuneration Committee be and is hereby authorized at its absolute discretion, to make such modifications, changes, variations, alterations or revisions in the Scheme, from time to time, or to suspend, withdraw or revive the Scheme, from time to time, as may be specified by any statutory authority and/or to give effect to any laws, rules, regulations, amendment(s) thereto and to do all other acts, deeds, matters and things as are necessary to give effect to the above authorization and to settle any questions or difficulties that may arise with regard to the creation, offer, issue, grant and allotment of stock options without requiring further consent or approval of the Board in this regard;

RESOLVED FURTHER THAT an annual status of the PVP ESOP Scheme 2026 and any recommendations or amendments shall be presented by the Committee before the Board for its consideration or any other regulatory compliances which the Board may be required to comply with.

RESOLVED FURTHER THAT any of the Directors or the Company Secretary of the Company be and are hereby severally authorized to do all such acts, deeds, matters and deal with all such matters and take all such steps as may be necessary and to sign and execute any deeds/ documents/ undertakings/ agreements/ papers/ writings, as may be required in this regard and matters connected therewith or incidental thereto.

12. APPROVAL FOR GRANTING OF EMPLOYEE STOCK OPTIONS TO AN IDENTIFIED EMPLOYEE EXCEEDING 1% (ONE PERCENT) OF THE ISSUED CAPITAL OF THE COMPANY AT THE TIME OF GRANT.

To consider and if thought fit, to pass the following resolution as a **Special Resolution:**

RESOLVED THAT pursuant to the provisions of Section 62(1)(b) read with Rule 12 of the Companies (Share Capital and Debentures) Rules, 2014 and all other applicable provisions, if any, of the Act read with the Rules framed thereunder, the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactments thereof for the time being in force), the MOA and AOA of the Company, and subject to such other approvals, permissions and sanctions as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions and sanctions, which may be accepted by the Board of the Company, approval and consent of the Shareholders of the Company ("Shareholders") be and is hereby accorded to create, offer and grant from time to time, in a financial year, employees stock options in excess of 1% of the issued capital of the Company (excluding outstanding warrants and conversions) at the time of grant of such options to such employees as may be decided by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee of the Company under PVP ESOP Scheme 2026 of the Company, on such terms and conditions as provided in the "PVP Ventures Limited Employees Stock Option Scheme 2026" ("PVP ESOP Scheme 2026") and as may be fixed or determined by the Board.

RESOLVED FURTHER THAT the maximum number of options granted to such employees of the Company under the PVP ESOP Scheme 2026 shall be the quantum of shares as may be decided by the Board based on the recommendation of the Nomination and Remuneration Committee and each option on exercise shall entitle the aforesaid employee to 1 (one) equity share of the Company.

RESOLVED FURTHER THAT the equity shares so issued and allotted as mentioned hereinabove shall rank pari-passu with the then existing equity shares of the Company."

13. TO EXTEND PVP VENTURES LIMITED EMPLOYEE STOCK OPTION SCHEME 2026 TO THE ELIGIBLE EMPLOYEES OF ITS ASSOCIATE AND SUBSIDIARY COMPANIES

To consider and if thought fit, to pass the following resolution as a **Special Resolution.**

RESOLVED THAT pursuant to the provisions of Section 62(1)(b) of the Companies Act, 2013 (hereinafter referred to as "Act"), the Companies (Share Capital and Debentures) Rules, 2014 (hereinafter referred to as "Companies Rules") and other applicable provisions, if any, of the Act, the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any modifications thereof or supplements thereto and any other applicable laws for the time being in force and subject to such other consents, permissions, sanctions and approvals as may be necessary and subject to such consents, permissions, sanctions and approvals, consent of the members of the Company, be and is hereby accorded to the Board to extend the benefits of "PVP Ventures Limited Employees Stock Option Scheme 2026" ("PVP ESOP Scheme 2026") proposed in the resolution number 12 above to Eligible Employees (as defined in the Scheme) of its associate and subsidiary companies (present or future) and to such other persons as may from time to time be allowed, under prevailing laws, rules and regulations, and/or amendments thereto from time to time, as identified on the basis of criteria prescribed by the Board, at such price or prices in one or more tranches and on such terms and conditions, as may be fixed or determined by the Board/ Committee in accordance with the PVP ESOP Scheme 2026;

RESOLVED FURTHER THAT any one of the Directors or the Company Secretary of the Company be and are hereby severally/ jointly authorized to do all such acts, deeds, matters and deal with all such matters and take all such steps as may be necessary and to sign and execute any deeds/ documents/ undertakings/ agreements/ papers/ writings, as may be required in this regard and matters connected therewith or incidental thereto."

NOTES:

1. Pursuant to the General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs (MCA) and circular issued by SEBI vide circular no. SEBI/ HO/ CFD/ CFDPoD-2/ P/ CIR/ 2024/ 133 dated October 3, 2024 ("SEBI Circular") and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time), companies are allowed to hold AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, AGM shall be conducted through VC / OAVM.
2. Pursuant to the above-mentioned Circulars, physical attendance of the Members is not required at the Annual General Meeting, and attendance of the Members through VC/OAVM will be counted for the purpose of reckoning the quorum under section 103 of the Companies Act, 2013 ("the Act").
3. Information, pursuant to Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations') and Secretarial Standard - 2 on General Meetings, issued by The Institute of Company Secretaries of India ("ICSI"), in respect of Director retiring by rotation seeking re-appointment at this AGM is furnished as Annexure to this Notice.
4. Since this Annual General Meeting is being held pursuant to the circulars through VC/OAVM, the requirement of attendance of members in person has been dispensed with. Accordingly, in terms of the circulars, the facility for appointment of proxies by the members will not be available for this Annual General Meeting and hence the proxy form, attendance slip and route map of Annual General Meeting are not annexed to this notice.
5. Corporate/Institutional Members are entitled to appoint authorised representatives to attend the AGM through VC/ OAVM on their behalf and cast their votes through remote e-voting or E voting at the AGM. Corporate/ Institutional Members intending to authorise their representatives to participate and vote at the Meeting are requested to send a certified copy of the Board resolution/authorisation letter to the Scrutiniser at e-mail ID mail@b5corp.com with a copy marked to evoting@kfintech.com and to the Company at cs@pvpglobal.com, authorising its representative(s) to attend through VC/OAVM and vote on their behalf at the Meeting, pursuant to section 113 of the Act. Corporate Members/ Institutional Investors (i.e. other than individuals, HUFs, NRIs etc.) can also upload their Board Resolution/ Power of Attorney/Authority Letter etc. by clicking on the "Upload Board Resolution/Authority Letter" displayed under the "e-voting" tab in their login.
6. Members may note that the VC/OAVM Facility, provided by NSDL, allows participation of at least 1,000 Members on a first-come-first-serve basis. The large shareholders (i.e. shareholders holding 2% or more shareholding), promoters, institutional investors, directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee and auditors can attend the AGM without any restriction on account of the first-come first-served principle
7. The Members can join the AGM in the VC/OAVM mode 30 minutes before the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice.
8. In case of joint holders attending the AGM, only such joint holder who is higher in the order of the names as per the Register of Members of the Company, as of the cut-off date, will be entitled to vote at the Meeting.
9. The Annual Report for FY 2025-26 is being sent only through electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. The Company shall send the physical copy of Annual Report FY 2025-26 to those Members who request the same at cs@pvpglobal.com mentioning their Folio No./DP ID and Client ID.
10. SEBI vide Circular Nos. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated July 31, 2023, and SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/135 dated August 04, 2023, read with Master Circular No. SEBI/HO/ OIAE/OIAE_ IAD-1/P/CIR/2023/145 dated July 31, 2023 (updated as on August 11, 2023), has established a common Online Dispute Resolution Portal ("ODR Portal") for resolution of disputes arising in the Indian Securities Market. Pursuant to above-mentioned circulars, post exhausting the option to resolve their grievances with the RTA/ Company directly and through existing SCORES platform, the investors can initiate dispute resolution through the ODR Portal (https://smartodr.in/login).
11. The Notice convening the AGM has been uploaded on the website of the Company at www.pvpglobal.com and can also be accessed from the relevant section of the websites of the Stock Exchanges i.e. BSE Limited, National Stock Exchange of India Limited at www.bseindia.com, www.nseindia.com respectively. The AGM Notice is also available on the website of NSDL at www.evoting.nsdl.com.
12. In terms of Regulation 40(1) of the SEBI Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from April 01, 2019, except in case of request received for transmission or transposition of securities. Transfers of equity shares in electronic form are effected through the depositories with no involvement of the Company. Further, SEBI had fixed March 31, 2021, as the cut- off date for the re-lodgement of transfer deeds and the shares that are re-lodged for transfer shall be issued only in dematerialized mode.
13. The requests for effecting transmission/transposition of securities shall be processed in the dematerialized form. In order to eliminate all risks associated with physical shares and avail various benefits of dematerialization. Members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company's Registrar and Transfer Agent, KFin Technologies Limited ("Registrar" or "RTA") at einward.ris@kfintech.com for assistance in this regard.
14. Members may please note that SEBI vide its Circular No. SEBI/ MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated the Listed Companies to issue securities in dematerialized form only while processing service requests viz. Issue of duplicate securities certificate; claim from unclaimed suspense account; renewal/exchange of securities certificate; endorsement; sub-division/splitting of securities certificate; consolidation of securities certificates/folios; transmission and transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR – 4, the format of which is available on the website of the Company's RTA, Kfin Technologies Limited at www.kfintech.com. It may be noted that any service request received by a member can be processed by RTA/the Company only after the folio is KYC Compliant.
15. Members are requested to intimate changes, if any, about their name, postal address, e-mail address, telephone/mobile numbers, PAN, power of attorney registration, Bank Mandate details, etc. to their Depository Participant ("DP") in case the shares are held in electronic form and to the Registrar in case the shares are held in physical form, in prescribed Form No. ISR-1, quoting their folio number and enclosing the self-attested supporting document. Further, Members may note that SEBI has mandated the submission of PAN by every participant in the securities market.

16. Members can avail of the facility of nomination in respect of shares held by them in physical form pursuant to the provisions of section 72 of the Act. Members desiring to avail of this facility may send their nomination in the prescribed Form No. SH-13 duly filled in to KFin at the above-mentioned address. Members holding shares in electronic form may contact their respective Depository Participants for availing this facility.
17. The Register of Members and Transfer Books of the Company will be closed from 01st September 2026 to 07th September 2026 (both days inclusive) for the purpose of AGM.
18. To support the Green Initiative, Members who have not yet registered their email addresses are requested to register the same with their DPs in case the shares are held by them in electronic form and with the Company in case the shares are held by them in physical form.
19. Members of the Company holding shares either in physical form or in electronic form as of the cut-off date 31st August 2026 may cast their vote by remote e-voting. The remote e-voting period commences on 04th September 2026, at 09:00 a.m. (IST) and ends on 06th September 2026, at 05:00 p.m. (IST). The remote e-voting module shall be disabled by NSDL for voting thereafter. Once the vote on a resolution is cast by the Member, the Member shall not be allowed to change it subsequently.
20. The voting rights of the Members (for voting through remote e-voting before the AGM and e-voting during the AGM) shall be in proportion to their share of the paid-up equity share capital of the Company as of the cut-off date of 31st August 2026. Subject to receipt of the requisite number of votes, the Resolutions passed by remote e-voting are deemed to have been passed as if they have been passed at the AGM i.e. 07th September 2026. The Notice of the AGM indicating the instructions for the remote e-voting process can be downloaded from the NSDL's website www.evoting.nsdl. com or the Company's website www.pvpglobal.com
21. Members will be provided with the facility for voting through an electronic voting system during the video conferencing proceedings at the AGM and Members participating at the AGM, who have not already cast their vote by remote e-voting, will be eligible to exercise their right to vote during such proceedings of the AGM. Members who have cast their vote by remote e-voting prior to the AGM will also be eligible to participate at the AGM but shall not be entitled to cast their vote again on such resolutions for which the Member has already cast the vote through remote e-voting.
22. Any person holding shares in physical form and non- individual shareholders, who acquires shares of the Company and becomes a Member of the Company after the dispatch of this Notice and holding shares as on the cut-off date, i.e.31st August 2026, may obtain the User ID and password by sending a request along with the requisite documents at evoting@nsdl.com.
23. The Members who are present during the AGM through VC/OAVM and have not cast their votes through remote e-voting, would be allowed to cast their vote during the AGM through e-voting.
24. Members who would like to express their views/ ask questions as a speaker at the Meeting may pre- register themselves by sending a request from their registered email address mentioning their names, DP ID and Client ID/folio number, PAN, and mobile number at cs@pvpglobal.com by 31st August 2026 by 05:30 PM (IST). Only those Members who have pre-registered themselves as a speaker on the dedicated email id cs@pvpglobal.com will be allowed to express their views/ask questions during the AGM.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period shall commence on 04th September 2026, at 09:00 A.M. (IST) and shall end on 06th September 2026, at 05:00 P.M. (IST). Thereafter, the remote e-voting module shall be disabled by NSDL for voting.

Members whose names appear in the Register of Members / Beneficial Owners as on the cut-off date, i.e., 31st August, shall be entitled to cast their vote electronically.

The voting rights of Members shall be in proportion to their shareholding in the paid-up equity share capital of the Company as on the cut-off date.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	• For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. • Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. • If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp • Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. • Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience.
Individual Shareholders holding securities in demat mode with CDSL	a. Users who have opted for the CDSL Easi / Easiest facility can login through their existing user id and password. The option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on the login icon & New System Myeasi Tab and then use your existing my easi username & password. b. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the e-Voting is in progress as per the information provided by the company. On clicking the e-Voting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there are also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. c. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. d. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from an e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use the Forget User ID and Forget Password option available at the above-mentioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. **Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.**
2. **Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.**
3. **A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.**

   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. **Your User ID details are given below:**

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	**Your User ID is:**
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. **Password details for shareholders other than Individual shareholders are given below:**
   a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
   c) How to retrieve your 'initial password'?
      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
      (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.
6. **If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:**
   a) Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
   b) Physical User Reset Password (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. **After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.**
8. **Now, you will have to click on "Login" button.**
9. **After you click on the "Login" button, Home page of e-Voting will open.**

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e- Voting system?

After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".

Now you are ready for e-Voting as the Voting page opens.

Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

Upon confirmation, the message "Vote cast successfully" will be displayed.

You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to mail@b5corp.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to cs@pvpglobal.com

In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to cs@pvpglobal.com. If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.

Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.

In terms of SEBI notification dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR E-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.

Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not caste their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.

The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH

VC/OAVM ARE AS UNDER:

Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of

"VC/OAVM" placed under:

"Join meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

Members are encouraged to join the Meeting through Laptops for better experience.

Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name, demat account number/folio number, email id, mobile number at (cs@pvpglobal.com). The same will be replied by the company suitably

CONTACT DETAILS

Company	Mr. B Vignesh Ram Company Secretary and Compliance Officer PVP Ventures Limited Registered Office: 9th Floor, Door No. 2, KRM Centre, Harrington Road, Chetpet Chennai – 600 031 CIN : L72300TN1991PLC020122 Email: cs@pvpglobal.com
Registrar & Share Transfer Agent	M/s. KFin Technologies Limited Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad – 500 032 Tel: +91-40-67161526 Fax : +91-40-23001153 E-mail: einward.ris@kfintech.com Website: www.kfintech.com
e-Voting Agency	National Securities Depository Limited ("NSDL") E-mail: evoting@nsdl.com Phone: 022- 22723333 / 8588
Scrutinizer	Mr K.V.S.Subramanyam, Practicing Company Secretary

General Instructions

The Board of Directors has appointed Mr.K.V.S.Subramanyam, Practicing Company Secretary,(Membership No. FCS 5400& CP No. 4815) as the Scrutinizer to scrutinize the remote e-voting process before the AGM as well as e-voting process during the AGM fairly and transparently.

The Scrutinizer shall, immediately after the conclusion of voting at the AGM, unblock the votes cast through e-voting (i.e. votes cast during the AGM and votes cast through remote e-voting) and will submit a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or any other person authorized by him in writing, who shall countersign the same. The results will be announced not later than 2 working days from the conclusion of the AGM. The result declared along with the Scrutinizer's Report shall be forwarded to National Stock Exchange of India Limited, BSE Limited where the shares of the Company are listed. The results along with the Scrutinizer's Report shall also be placed on the website of NSDL, and will also be displayed on the Company's website at www.pvpglobal.com. Members seeking any information with regard to the financial statements or any matter to be placed at the AGM, are requested to write to the Company on or before 31st August 2026 through e-mail on cs@pvpglobal.com. The same will be replied by the Company suitably.

ANNEXURE TO THE NOTICE

STATEMENT OF MATERIAL FACTS PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013 AND ADDITIONAL INFORMATION ON DIRECTOR RECOMMENDED FOR APPOINTMENT / REAPPOINTMENT AS REQUIRED UNDER REGULATION 36 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AND SECRETARIAL STANDARDS ON GENERAL MEETINGS ISSUED BY THE INSTITUTE OF COMPANY SECRETARIES OF INDIA.

Item No. 3

The Members of the Company, at the Extraordinary General Meeting held on 06th March, 2026, approved the appointment of M/s. CNGSN & Associates LLP, Chartered Accountants (Firm Registration No. 004915S) as the Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of the erstwhile Statutory Auditors, M/s. PSDY & Associates, Chartered Accountants. In accordance with Section 139(8) of the Companies Act, 2013, M/s. CNGSN & Associates LLP hold office up to the conclusion of this Annual General Meeting.

Based on the recommendation of the Audit Committee, the Board of Directors has recommended the appointment of M/s. CNGSN & Associates LLP, Chartered Accountants (Firm Registration No. 004915S) as the Statutory Auditors of the Company for a term of five consecutive years, commencing from the conclusion of this Annual General Meeting until the conclusion of the Annual General Meeting of the Company to be held in the calendar year 2031.

M/s. CNGSN & Associates LLP have conveyed their consent to act as the Statutory Auditors of the Company and have confirmed that:

They are eligible for appointment and are not disqualified from being appointed as the Statutory Auditors under the provisions of the Companies Act, 2013;

Their appointment satisfies the criteria provided under Sections 139 and 141 of the Companies Act, 2013;

They hold a valid Peer Review Certificate issued by the Institute of Chartered Accountants of India (ICAI); and

The proposed appointment is in compliance with all applicable statutory requirements.

The Audit Committee and the Board have considered the qualifications, experience, professional competence, independence, peer review status, experience in auditing listed entities and the quality of audit services rendered by the firm while recommending their appointment for the first term of five consecutive years.

The remuneration payable to the Statutory Auditors shall be determined by the Board of Directors (including the Audit Committee thereof) in consultation with the Statutory Auditors, based on the scope of audit and such other permissible assignments as may be undertaken from time to time.

The brief profile of the proposed Statutory Auditors is provided below:

Particulars	Details
Name of Auditor	M/s. CNGSN & Associates LLP
Firm Registration No.	004915S
Proposed Term	Five consecutive years commencing from the conclusion of this AGM till the conclusion of the AGM to be held in the calendar year 2031
Brief Profile	M/s. CNGSN & Associates LLP is a well-established firm of Chartered Accountants with a committed team of professionals headed by experienced Chartered Accountants and having offices across South India. The firm possesses significant experience in statutory audits of listed companies and other large corporates and holds a valid Peer Review Certificate issued by ICAI.
Disclosure of relationship with Directors	None

Item No 4.

In terms of Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, all material related party transactions shall require prior approval of the shareholders by a special resolution, related parties shall abstain from voting. During the financial year 2026–27, the Company proposes to enter into transactions with M/s. BVR Malls Private Limited, PV Potluri Ventures Private Limited, Humain Healthtech Private Limited, Apta Medical Imaging Private Limited, Noble Diagnostics Private Limited, Biohygea Global Private Limited, Optimus Oncology Private Limited and 7 Med India Private Limited which are a Related Party as defined under Section 2(76) of the Companies Act, 2013 an applicable SEBI Regulations. The proposed transactions may include the following: Purchase or sale of goods or services Leasing of property or assets Availing or rendering of any consultancy, technical, operational, or administrative services Loans, advances, investments, guarantees, interest or securities (if any) The estimated aggregate value of such transactions during FY 2026-2027 is expected to exceed the materiality threshold of 10% of the annual consolidated turnover of the Company, as per the last audited financial statements. All transactions will be conducted on an arm's length basis and in the ordinary course of business, and will be reviewed and approved by the Audit Committee periodically.

Item No. 5

The Board of Directors of the Company at its Meeting held on 15 May 2026 approved the proposal to change the name of the Company from PVP Ventures Limited to Evervie Health Limited, subject to approval of the Members and statutory authorities.

Over the last few years, the Company has undertaken significant strategic initiatives to diversify and expand its business operations in the healthcare and life sciences sector. The Board believes that the proposed name Evervie Health Limited more appropriately reflects the Company's present business strategy, future growth plans and long-term vision.

The proposed change of name is intended to align the Company's corporate identity with its evolving business portfolio and enhance stakeholder recognition of the Company's strategic direction.

The Ministry of Corporate Affairs has approved reservation of the proposed name. Upon receipt of shareholders' approval and all necessary statutory approvals, the Registrar of Companies will issue a fresh Certificate of Incorporation consequent upon change of name.

The proposed change of name will not affect any rights of the Members or creditors of the Company. The Company's legal status as a corporate entity shall remain unchanged and all existing contracts, agreements, licences, approvals, rights and obligations shall continue to remain valid and enforceable.

The Board recommends passing of the Special Resolution set out at Item No. 5.

None of the Directors, Key Managerial Personnel or their relatives are concerned or interested in the Resolution except to the extent of their shareholding, if any, in the Company.

Item No. 6

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its Meeting held on 15 May 2026 appointed Ms. Saloni Khandelwal as an Additional Director in the capacity of Non-Executive Independent Director with effect from 15 May 2026, subject to approval of the Members.

Ms. Saloni Khandelwal is an accomplished transaction advisory professional with nearly two decades of experience across mergers and acquisitions, business restructuring, tax advisory, fundraising, investment strategy and corporate structuring. She is the Founder of Transaction Square and was previously associated with PwC as a Partner in the Mergers & Acquisitions Tax practice. Prior thereto, she held leadership positions with KPMG. She has advised several domestic and international businesses across healthcare, pharmaceuticals, infrastructure, real estate, media and technology sectors.

The Board believes that her extensive expertise in strategic transactions, governance, mergers and acquisitions, fundraising and regulatory matters will significantly strengthen the Board and contribute to the Company's strategic transformation into a healthcare-focused enterprise.

The Company has received:

Consent to act as a Director in Form DIR-2;

Declaration that she is not disqualified under Section 164 of the Companies Act, 2013;

Declaration of Independence under Section 149(7) of the Companies Act, 2013;

Confirmation that she meets the criteria of independence prescribed under the Companies Act, 2013 and the SEBI Listing Regulations;

Confirmation that she is not debarred from holding the office of Director by SEBI or any other statutory authority.

In the opinion of the Board, Ms. Saloni Khandelwal fulfils the conditions specified under the Companies Act, 2013, the Rules made thereunder and the SEBI Listing Regulations for appointment as an Independent Director and is independent of the Management.

The Board considers that her appointment would be of immense benefit to the Company.

Accordingly, the Board recommends the Ordinary Resolution set out at Item No. 6 for approval of the Members.

Except Ms. Saloni Khandelwal and her relatives, none of the Directors, Key Managerial Personnel of the Company or their relatives is, in any way, concerned or interested, financially or otherwise, in the Resolution.

Particulars	**Details**
Name	Ms. Saloni Khandelwal
DIN	00014590
Designation	Non-Executive Independent Director
Date of first appointment	15 May 2026
Term	Five consecutive years (15 May 2026 – 14 May 2031)
Liable to retire by rotation	No
Qualification	Chartered Accountant
Expertise	M&A, Tax, Fund Raising, Corporate Structuring, Family Office Advisory
Remuneration sought to be paid	Sitting Fees and Commission as approved by the Board/Shareholders
Shareholding	Nil*
Relationship with Directors/KMP	None
Directorships	The same is disclosed in the other part of this report.
Committee Memberships	The same is disclosed in the other part of this report.
Board Meetings attended From the date of appointment till AGM	Two

Item No. 7

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, at its meeting held on 15 May 2026, appointed Mr. Srivatsan Kalyanasundaram as an Additional Director in the category of Non-Executive Independent Director with effect from 15 May 2026, subject to the approval of the Members.

Mr. Srivatsan Kalyanasundaram is an accomplished global business leader with nearly three decades of experience across multinational corporations, technology-led enterprises and regulated industries. He has held senior leadership positions with globally reputed organisations including Vodafone Group and McKinsey & Company and has extensive international experience across the United Kingdom, Europe and the Middle East.

He currently serves as Chief Executive Officer Advisor and Interim Chief Operating Officer of a Public Investment Fund-backed fintech platform in the Kingdom of Saudi Arabia. His expertise spans corporate strategy, technology, governance, cybersecurity, digital transformation, organisational scale-up and leadership of businesses operating in highly regulated environments. He holds an MBA from HEC Paris/Ross School of Business, an M.Sc. in Economics and a Bachelor's Degree in Engineering from BITS Pilani.

Considering the Company's strategic transformation and its focus on healthcare, life sciences and global expansion, the Board is of the view that Mr. Srivatsan's extensive international business experience, governance expertise and technology leadership will significantly strengthen the Board and provide valuable strategic guidance to the Company.

The Company has received:

Consent to act as Director in Form DIR-2;

Declaration confirming that he is not disqualified under Section 164 of the Companies Act, 2013;

Declaration of Independence under Section 149(7) of the Companies Act, 2013;

Confirmation that he satisfies the criteria of independence prescribed under the Companies Act, 2013 and the SEBI Listing Regulations;

Confirmation that he is not debarred from holding the office of Director by SEBI or any other statutory authority.

In the opinion of the Board, Mr. Srivatsan Kalyanasundaram fulfils the conditions specified under the Companies Act, 2013 and the SEBI Listing Regulations for appointment as an Independent Director and is independent of the management.

The Board further believes that his appointment will add significant value to the Company's Board by bringing international strategic leadership, governance expertise and digital transformation experience.

Accordingly, the Board recommends the Ordinary Resolution set out at Item No. 7 for approval of the Members.

Except Mr. Srivatsan Kalyanasundaram and his relatives, none of the Directors, Key Managerial Personnel of the Company or their relatives is concerned or interested, financially or otherwise, in the Resolution.

Particulars	Details
Name	Mr. Srivatsan Kalyanasundaram
DIN	11719208
Designation	Non-Executive Independent Director
Date of first appointment	15 May 2026
Term	Five consecutive years (15 May 2026 – 14 May 2031)
Liable to retire by rotation	No
Qualification	MBA (HEC Paris/Ross School of Business), M.Sc. (Economics), B.E. (BITS Pilani)
Expertise	Strategy, Corporate Governance, Digital Transformation, Technology, Cybersecurity, International Business, Regulated Industries
Remuneration sought to be paid	Sitting Fees and Commission as approved by the Board/Shareholders
Shareholding	Nil*
Relationship with Directors/KMP	None
Directorships	The same is disclosed in the other part of this report.
Committee Memberships	The same is disclosed in the other part of this report.
Board Meetings attended From the date of appointment till AGM	Two

Item No 8.

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, at its meeting held on 15th May, 2026, appointed Dr. Ellen Feehan as an Additional Director of the Company with effect from 15th May, 2026, subject to the approval of the Members. The Board has also recommended her appointment as the Executive Director and Chief Executive Officer of the Company for a period of five (5) consecutive years, commencing from 15th May, 2026, together with payment of remuneration.

Dr. Ellen Feehan is a qualified medical doctor and management professional. She graduated from Trinity College Dublin with qualifications of MB, BCh, BAO, holds an MBA from University College Dublin and has also obtained professional qualifications in Surgery and Plastic Surgery from the Royal College of Surgeons in Ireland, including FRCSI and FRCS (Plast). She has extensive experience in healthcare strategy, clinical leadership, healthcare management and business transformation.

The Board is of the view that Dr. Ellen Feehan's international healthcare experience, strategic leadership capabilities and domain expertise will significantly strengthen the executive leadership of the Company and support its strategic transformation into a healthcare and life sciences focused enterprise.

The Company has received from Dr. Ellen Feehan her consent to act as a Director, declaration that she is not disqualified from being appointed as a Director under Section 164 of the Companies Act, 2013 and other necessary declarations and confirmations as required under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As the Company has inadequate profits, approval of the Members by way of a Special Resolution is being sought for payment of remuneration to Dr. Ellen Feehan in accordance with the provisions of Sections 196, 197 and Schedule V of the Companies Act, 2013. The remuneration proposed is considered reasonable having regard to her qualifications, experience, responsibilities and the size and nature of the Company's business.

The terms and conditions of appointment of Dr. Ellen Feehan are available for inspection by the Members at the Registered Office of the Company during business hours on all working days up to the date of the Annual General Meeting.

The Board considers that the appointment of Dr. Ellen Feehan as the Executive Director and Chief Executive Officer is in the best interests of the Company and accordingly recommends the Special Resolution set out at Item No. 8 for approval of the Members.

Except Dr. Ellen Feehan and her relatives, none of the Directors, Key Managerial Personnel of the Company or their relatives is, in any way, concerned or interested, financially or otherwise, in the proposed Resolution, except to the extent of their shareholding, if any, in the Company.

Particulars	Details
Name	Dr. Ellen Feehan
DIN	11716152
Designation	Executive Director & Chief Executive Officer
Date of first appointment	15 May 2026
Term	Five consecutive years (15 May 2026 – 14 May 2031)
Liable to retire by rotation	No
Qualification	MB, BCh, BAO (Trinity College Dublin); MBA (University College Dublin); FRCSI; FRCS (Plast)
Expertise	Extensive international experience in healthcare, clinical leadership, healthcare management, strategic planning and organisational transformation. Healthcare, Clinical Leadership, Strategic Management, Healthcare Operations, Corporate Leadership and Business Transformation
Remuneration sought to be paid	As set out in the Resolution and approved by the Members
Shareholding	Nil*
Relationship with Directors/KMP	None
Directorships	The same is disclosed in the other part of this report.
Committee Memberships	The same is disclosed in the other part of this report.
Board Meetings attended From the date of appointment till AGM	Two

Item No 9.

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, at its Meeting held on 15th May, 2026, approved the appointment of Dr. Neeraja Nagarajan as the Chief Operating Officer of the Company and as an Additional Director of the Company with effect from 1st July, 2026, subject to the approval of the Members. The Board now recommends her appointment as a Director of the Company, not liable to retire by rotation, with effect from 1st July, 2026.

Dr. Neeraja Nagarajan is a distinguished medical doctor, public health scientist and healthcare strategist with extensive experience in healthcare systems, operational excellence and business transformation. She has previously been associated with McKinsey & Company, where she advised leading healthcare organisations on strategic planning, healthcare delivery models and operational transformation initiatives. Her expertise spans healthcare management, public health advisory, operational strategy and execution of large-scale transformation programmes.

The Company is pursuing a strategic transformation with a strong focus on the healthcare and life sciences sector. The Board believes that Dr. Neeraja Nagarajan's extensive experience and deep understanding of healthcare strategy and operations will significantly strengthen the leadership of the Company and contribute towards achieving its long-term strategic objectives.

The Company has received from Dr. Neeraja Nagarajan her consent to act as a Director, declaration confirming that she is not disqualified from being appointed as a Director under Section 164 of the Companies Act, 2013 and all other declarations, disclosures and confirmations required under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In the opinion of the Board, Dr. Neeraja Nagarajan possesses the requisite qualifications, experience, integrity, expertise and proficiency for appointment as a Director of the Company. The Board considers that her association with the Company will be of immense value in strengthening its strategic and operational capabilities.

Accordingly, the Board recommends the Special Resolution set out at Item No. 9 for approval of the Members.

As the Company has inadequate profits, approval of the Members by way of a Special Resolution is being sought for payment of remuneration to Dr. Neeraja Nagarajan in accordance with the provisions of Sections 196, 197 and Schedule V of the Companies Act, 2013. The remuneration proposed is considered reasonable having regard to her qualifications, experience, responsibilities and the size and nature of the Company's business. Except Dr. Neeraja Nagarajan and her relatives, none of the Directors, Key Managerial Personnel of the Company or their relatives is, in any way, concerned or interested, financially or otherwise, in the proposed Resolution, except to the extent of their shareholding, if any, in the Company.

Particulars	Details
Name	Dr. Neeraja Nagarajan
DIN	11716150
Designation	Director and Chief Operating Officer
Date of first appointment	01st July 2026
Term	Five consecutive years (01 July 2026 – 30 June 2026)
Liable to retire by rotation	No
Qualification	Medical Doctor; Public Health Scientist

Particulars	Details
Expertise	Extensive experience in healthcare, public health, healthcare strategy, operational excellence and organisational transformation Healthcare Strategy, Public Health, Operations, Business Transformation, Healthcare Management
Remuneration sought to be paid	As set out in the Resolution and approved by the Members
Shareholding	Nil*
Relationship with Directors/KMP	None
Directorships	The same is disclosed in the other part of this report.
Committee Memberships	The same is disclosed in the other part of this report.

Item No 10

Mr. Prasad V. Potluri is the Chairman and Managing Director of the Company and has been providing strategic leadership and direction to the Company. Considering his extensive experience, leadership and significant contribution towards the growth and strategic initiatives of the Company, the Nomination and Remuneration Committee and the Board of Directors have approved, subject to the approval of the Members, payment of managerial remuneration of Rs.5,00,00,000/- (Rupees Five Crores only) to him for the Financial Year 2026-27.

The Company expects that during the Financial Year 2026-27, it may have no profits or its profits may be inadequate within the meaning of Section 197 of the Companies Act, 2013. Accordingly, in terms of the provisions of Section 197 read with Section II of Part II of Schedule V to the Companies Act, 2013, approval of the Members is being sought by way of a Special Resolution for payment of the aforesaid remuneration.

Further, in order to enable the Company to avail loans, borrowings and other credit facilities on competitive terms, Mr. Prasad V. Potluri has agreed to provide, and may continue to provide, collateral securities and personal guarantees in favour of banks, financial institutions and other lenders. Such support enables the Company to enhance its borrowing capacity and secure financial assistance on commercially favourable terms.

Considering the financial exposure and obligations undertaken by Mr. Prasad V. Potluri, the Board of Directors, based on the recommendation of the Audit Committee, has approved payment of fees at the rate of 2% per annum on the value of collateral securities provided by him and 1% per annum on the value of personal guarantees furnished by him in connection with the Company's borrowings, subject to the approval of the Members.

Since Mr. Prasad V. Potluri is a Related Party of the Company, the aforesaid transaction also constitutes a Related Party Transaction under the applicable provisions of the Companies Act, 2013 and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee has reviewed the terms of the proposed transaction and recommended the same to the Board, being satisfied that the transaction is in the best interests of the Company.

The Board is of the opinion that the proposed remuneration and the fees payable towards collateral securities and personal guarantees are fair, reasonable and commensurate with the responsibilities discharged by Mr. Prasad V. Potluri and the financial support extended by him for the benefit of the Company.

Since the Company has reported inadequate profits during FY 2025–26, the proposed remuneration exceeds the limits specified under Section 197 read with Schedule V of the Companies Act, 2013, and falls within the ambit of Regulation 17(6)(e) & 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates shareholders' approval by special resolution when the remuneration to Executive Directors who are Promoters exceeds the specified thresholds.

The other statutory details are presented below

I. Background and Industry Overview Nature of Industry: The Company operates in the field of Health Care and Real Estate Financial Performance: The Company reported inadequate profits for the year 2025–26, as a result, remuneration beyond statutory thresholds requires approval under Schedule V of the Companies Act, 2013.

II. Profile of Mr. Prasad Veera Potluri Education & Experience: Mr Prasad V Potluri is the Chairman and Managing Director of the company and he is also the Promoter of the company. Mr. Potluri has provided strategic leadership and operational guidance, enabling the Company to sustain operations during challenging market conditions and diversify into healthcare projects.

Past Remuneration: Mr Prasad V Potluri has not drawn any salary. Benchmarking: Proposed remuneration is in line with industry benchmarks for similar roles in comparable listed companies. Pecuniary Relationship: Apart from the proposed remuneration, there is no pecuniary relationship with the Company.

III. Remuneration Structure Amount: Rs 5,00,00,000 (Rupees Five Crores only) per annum—comprehensive of salary, allowances, perquisites, performance incentives, and all other benefits.

Tenure: Applicable for FY 2026–27

Other Terms: Not applicable.

IV. Justification & Company's Future Outlook: The Board anticipates improved performance from ongoing real estate projects and healthcare ventures in FY 2026-27

V. Related Party Transaction (RPT) Disclosures (Under SEBI LODR Reg. 23)

Policy & Materiality: The Company has a policy on material RPTs, approved by the Board and reviewed periodically. Materiality threshold is set at Rs 1,000 crore or 10% of consolidated turnover—whichever is lower. Audit Committee Approval: Since, Mr Prasad V Potluri is the Promoter of the company, the Board sought the approval of the Audit Committee the Nomination and Renumeration Committee. Shareholder Approval: Since the proposed remuneration is material RPT exceeding the thresholds, shareholders' approval via Special Resolution is being sought in line with Regulation 23(4) and related parties shall abstain from voting.

VI. Information Under Regulation 36(6) of SEBI LODR As mandated, the following information is provided: Summary of information presented to the Audit Committee: includes nature and terms of remuneration, tenure, financial comparisons, and qualified justification. Audit Committee recommendation: The Committee (comprising independent directors) unanimously recommended approval, considering alignment with market standards and Company performance outlook.

Valuation / External Reports: No external valuation required. Mr. Prasad V. Potluri has not drawn any remuneration since the inception of the Company; therefore, comparison with past remuneration metrics is not applicable.

Other Information: Not Applicable.

Except Mr. Prasad V. Potluri and his relatives, to the extent of their shareholding, if any, none of the Directors, Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in the Resolution.

The Board of Directors recommends the Special Resolution set out at Item No.10 of the Notice for approval of the Members.

Item Nos 11, 12 & 13

The Company is planning to implement/commence an PVP Ventures Limited Employee Stock Option Scheme 2026 ("PVP ESOP Scheme 2026") to promote the long-term financial interest in the Company by offering Eligible Employees an opportunity to participate in the share capital of the Company, to attract and retain high-quality human talent by providing them incentives and reward opportunities, to motivate talented and critical Employees and create a sense of ownership among the Employees of the Company, to improve the Employee performance with ownership interests and provide them with wealth creation opportunity whilst in employment with the Company and to achieve sustained growth by aligning Employee interest with long term interests of the Company.

The Board of Directors of the Company at its meetings held on 24th July 2026 had approved the PVP ESOP Scheme 2026, subject to the approval of the members. The Scheme has been formulated in accordance with the Companies Act, 2013 ("the Act") read with the Companies (Share Capital and Debentures) Rules, 2014 ("Companies Rules") and the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI (SBEB) Regulations").

Brief description of the Scheme:

The Company proposes to introduce the Scheme with a view to attract, retain, incentivize and motivate employees and directors of the Company, its subsidiary companies and associate companies.

The Scheme contemplates grant of employee stock options ("Options") to the eligible employees as may be determined in due compliance of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. After vesting, the eligible employees earn a right (but not obligation) to exercise the vested Options within the predefined exercise period.

The Nomination and Remuneration Committee shall administer the Scheme. All questions of interpretation of the Scheme shall be determined by the Nomination and Remuneration Committee and such an interpretation shall be final and binding upon all the persons having an interest in the Scheme.

Total number of options to be granted:

The total number of Options to be granted under PVP ESOP Scheme 2026 shall be 2,00,00,000 accordance with the terms and conditions of such issue.

The SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 require that in case of any corporate action(s) such as rights issues, bonus issues, merger and sale of division and others, a fair and reasonable adjustment needs to be made to the Options granted. In this regard, the Nomination and Remuneration Committee shall adjust the number and exercise price of the Options granted in such a manner that the total value of the Options granted under PVP ESOP Scheme 2026 remains the same after any such corporate action. Accordingly, if any additional Options are issued by the Company to the Option grantees for making such fair and reasonable adjustment, such number of shares additionally issued shall be deemed to be increased to the extent of such additional Options issued.

If an Option expires, lapses or becomes un-exercisable due to any reason, it shall be brought back to the Options pool and shall become available for future grants, subject to compliance with the provisions of the Applicable Laws.

Thus, all the Employees meeting the eligibility criteria as may be determined by the Nomination and Remuneration Committee from time to time and who join the Company and / or its subsidiary Companies and/ or its associate companies hereafter would also be entitled to the benefit under Scheme.

For employees joining in future, fulfil the eligibility criteria may be determined by the Nomination and Remuneration Committee, they would be granted options on such future dates as may be determined by the Nomination and Remuneration Committee.

Identification of classes of Employees entitled to participate in Scheme

Following classes of employees of the Company, it's Subsidiary or Associate companies ("Employees") are entitled to participate in Scheme:

a) an employee as designated by the company, who is exclusively working in India or outside India; or

b) a director of the company, whether a whole time director or not, including a non-executive director who is not a promoter or member of the promoter group, but excluding an independent director.

c) an employee as defined in sub-clauses (a) or (b), of a group company including subsidiary or its associate company, in India or outside India, or of a holding company of the company, but does not include—

   i. an employee who is a promoter or a person belonging to the promoter group; or

   ii. a director who, either himself or through his relative or through any body corporate, directly or indirectly, holds more than ten per cent of the outstanding equity shares of the company;

Requirements of vesting and period of vesting:

Options granted under the Scheme would vest not earlier than minimum vesting period of 1 (One) year subject to such other conditions imposed by the Nomination and Remuneration Committee.

Options shall vest essentially based on continuation of employment as per requirement of the SEBI (Share Based Employee Benefits and Sweat Equity)Regulations, 2021. Besides continuity of employment, Options under the proposed Scheme shall vest for Employees on the basis of corporate performance / individual performance or such other parameters as may be prescribed by the Nomination and Remuneration Committee.

Options granted would vest essentially on the basis of continuation of employment / service as on relevant date of vesting as a pre-requisite condition, provided that the eligible employee is not under any notice of resignation or termination. In case of death and permanent incapacity of an eligible employee in employment or service, condition of minimum vesting period of 1 (One) year shall not apply, in which case all the Options granted up to the death or permanent incapacity, as the case may be, shall vest as on date of such event.

Maximum period within which the options shall be vested:

The Maximum period of vesting within which the option shall be vested shall be determined by the Nomination and Remuneration Committee as decided from time to time.

Exercise price or pricing formula:

The Exercise Price shall be decided by the Nomination and Remuneration Committee at its discretion from time to time. However, the Exercise Price shall not be less than the face value of the Shares of the Company.

Exercise period and the process of exercise:

The exercise period would commence from the date of vesting and will expire on completion of 10 (ten) years from the date of respective vesting or such other period as may be decided by the Nomination and Remuneration Committee, from time to time.

The vested Options, as permitted under the Scheme, shall be exercisable by the Employees by a written application to the Company expressing their desire to exercise such Options in such manner and in such format and in such numbers as may be prescribed by the Nomination and Remuneration Committee from time to time. The vested Options shall lapse, if not exercised within the specified exercise period.

Appraisal process for determining the eligibility of Employees under Scheme:

The appraisal process for determining eligibility shall be decided from time to time by the Nomination and Remuneration Committee. The broad criteria for appraisal and selection may include parameters like tenure of association with the Company, performance during the previous years, contribution towards strategic growth, contribution to team building & succession, cross-functional relationship, corporate governance, etc.

Maximum number of options to be issued per employee and in aggregate:

The maximum number of Options that shall be granted to each Employee shall vary depending upon the designation and the appraisal / assessment process. The Nomination and Remuneration Committee reserves the right to decide the number of Options to be granted and the maximum number of Options that can be granted to each employee.

Maximum quantum of benefits to be provided per employee under the Scheme:

No benefit other than by way of grant of Options is envisaged under the Scheme.

Implementation or administration of the Scheme:

The Scheme shall be implemented and administered directly by the Nomination and Remuneration Committee of the Company.

Source of acquisition of shares under the Scheme:

PVP ESOP Scheme 2026 envisages issue of new shares against exercise of Vested Options.

Amount of loan to be provided for implementation of the scheme(s) by the Company to the trust, its tenure, utilisation, repayment terms, etc.:

This is currently not applicable under the present Scheme.

Maximum percentage of secondary acquisition:

PVP ESOP Scheme 2026 envisages issue of new shares and there is no contemplation of secondary acquisition.

Accounting and Disclosure Policies:

The Company shall follow the laws / regulations applicable to accounting and disclosure related to Employee Stock Options and Accounting Standard IND AS 102 on Share based payments and / or any relevant Accounting Standards as may be prescribed by the competent authorities from time to time, including the disclosure requirements prescribed therein in due compliance with the requirements of Regulation 15 of the SEBI SBEB Regulations.

Method of Option valuation:

The Company shall adopt the 'fair value method' for valuation of the Options as prescribed under guidance note or under any relevant accounting standard notified by the appropriate authorities from time to time.

Period of lock-in:

The Shares issued upon exercise of the Options shall be freely transferable and shall not be subject to any lock-in period restriction after such allotment and credit to the respective demat account; however the same shall be subject to such restrictions as may be prescribed under applicable laws including the Company's Code of Conduct to regulate, monitor and report trading by insiders, under the Securities and Exchange Board of India (Prohibition of Insider Trading), Regulations, 2015, as amended.

Terms and conditions for buyback, if any, of specified securities granted under the Scheme:

Subject to the provisions of the then prevailing applicable laws, the Nomination and Remuneration Committee shall determine the procedure for buy-back of the Options granted under the Scheme if to be undertaken at any time by the Company, and the applicable terms and conditions thereof.

The consent of the shareholders is being sought pursuant to Section 62(1)(b) read with Rule 12 of the Companies (Share Capital and Debentures) Rules, 2014 and all other applicable provisions, if any, of the Act read with Regulation 6 of the SEBI (Share Based Employee Benefits and Sweat Equity)Regulations, 2021 for implementation of PVP ESOP Scheme 2026.

In light of the above, the Board recommends passing of the resolutions as set out under Item Nos. 11, 12 & 13 of the Notice for approval of the members as a special resolution.

Further, considering the scale of business of the Company and the responsibilities, contribution and on-going efforts of the eligible employees of the Company, the board of directors based on the recommendation of the Nomination and Remuneration Committee shall allot shares to such employees exceeding 1% of the current issued share capital of the Company.

None of the Directors or Key Managerial Personnel of the Company including their relatives are, in any way, concerned or interested, financially or otherwise, in the proposed resolution set out at Item No. 11, 12 and 13 of this Notice.

The Board recommends passing of the resolutions as set out under Item No. 11, 12 and 13 of the Notice for approval of the members as a special resolution.

The Board of Directors recommend implementation of PVP ESOP Scheme 2026 for the employees of the Company and its subsidiary and associate companies. In the light of the above, you are requested to accord your approval to the Special Resolutions as set out at Agenda Item Nos.11, 12 and 13 of the accompanying Notice.

A draft copy of PVP ESOP Scheme 2026 is available for inspection at the Registered office of the Company between 2.00 p.m. and 5.00 p.m. on all working days (except Saturdays, Sundays and Holidays). The same is also available on the website of the Company, www.pvpglobal.com to facilitate online inspection till the conclusion of the ensuing Annual General Meeting.

None of the Directors and Key Managerial Personnel of the Company and their relatives has any concern or interest, financial or otherwise, in the proposed resolution, except to the extent of their entitlements determined lawfully, if any, under the scheme.

The Board recommends passing of the resolutions as set out under Item Nos. 11, 12 & 13 of the Notice for approval of the members as a special resolution